New Data Presented at AHA Scientific Sessions 2026 Demonstrate That CARDAMYST® (etripamil) Nasal Spray Converted Recurrent PSVT to Normal Heart Rhythm in Patients with Prior Catheter Ablation

Milestone Pharmaceuticals reported that CARDAMYST (etripamil) nasal spray restored normal heart rhythm within 30 minutes in approximately two-thirds of patients with recurrent symptomatic PSVT after prior catheter ablation. The announcement presents positive clinical data for the cardiovascular medicine.

Analysis

This is incremental product validation, not yet evidence for a material change in MIST’s earnings trajectory. The commercial read-through depends on whether post-ablation recurrences are a sizeable, reachable treatment segment and whether clinicians and patients adopt an at-home rescue option; neither is established by a response rate alone. If confirmed, the result could support broader physician comfort with etripamil in episodic PSVT, but it does not imply fewer ablations or a change in standard care.

The immediate risk is a promotional-data rally outrunning the evidence. The release does not provide sample size, study design, comparator, statistical uncertainty, safety detail, or durability, so the apparent response should not be extrapolated to the overall PSVT population. Over the next 1–3 months, prioritize fuller data and any label, access, or prescribing updates. Over 6–18 months, the key test is repeat use and commercial uptake, not another isolated efficacy headline. A lack of confirmatory detail, safety concerns, or weak adoption would reverse the positive read-through.

Key Decisions for Investors

• Do not chase a gap higher on the release alone. Treat MIST as an event-driven watch pending the full dataset and clarification of the post-ablation subgroup’s size, protocol, confidence intervals, and safety profile.
• Conditional trade: consider a small, risk-defined MIST long only after fuller data corroborate the finding and the stock holds its post-news move; otherwise wait. No defensible price target or options structure can be set from the supplied information.
• Track 1–3 month catalysts: detailed presentation or filing, regulatory/label updates, and evidence of clinician access and prescribing. Verify whether the studied use is within the current label before assigning commercial value.
• Falsify the thesis if detailed results materially weaken the reported response, reveal an unfavorable safety profile, or subsequent company updates fail to show adoption; reassess any long exposure in that case.